Head-to-head evidence
AG2304R vs Atozet (ezetimibe/atorvastatin)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: HMG-CoA reductase / NPC1L1 · full Atherosclerotic Cardiovascular Disease pipeline
AG2304R
Developed by Ahn-Gook Pharmaceutical
NCT06717360 · Phase 3 · completed
The study randomly assigned 158 participants and used quadruple masking with AG2304R as an active comparator. Its primary endpoint was LDL-C, a surrogate biomarker, and the outcome comparison cannot yet be assessed because results are not posted.
Atozet (ezetimibe/atorvastatin)
Developed by Organon
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AG2304R's landscape · Atozet (ezetimibe/atorvastatin)'s landscape